Plan for Microwave Thermal Field

Hepatocellular Carcinoma Clinical Trial

Official title:

Research on Intelligent System of Plan for Microwave Thermal Field for Hepatocellular Carcinoma

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05270642
• Other study ID #: S2021-439-01
• Status: Active, not recruiting
• Phase: N/A
• Start date: October 1, 2021
• Est. completion date: December 30, 2022

Study information

• Verified date: February 2022
• Source: Chinese PLA General Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Develop an intelligent system based on contrast-enhanced ultrasound and clinical information to help doctors automatically obtain ablation parameters (ablation needle number, ablation needle type, ablation time,ablation power) when preparing to use microwave ablation to treat hepatocellular carcinoma

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 5
• Est. completion date: December 30, 2022
• Est. primary completion date: December 30, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Biopsy or clinical diagnosis of HCC

2. Complete clinical information and preoperative CEUS

3. Curative treatment

Exclusion Criteria:

1. Palliative care

2. Intolerance to ablation

3. Severe coagulation disorder

Related Conditions & MeSH terms

• Ablation
• Carcinoma
• Carcinoma, Hepatocellular
• Hepatocellular Carcinoma

Intervention

Procedure:
• Microwave Thermal guided by Plan for Microwave Thermal Field system
When HCC patients undergo microwave ablation, the doctor will refer to the ablation plan provided by the system.If the plan is consistent with what the doctor thinks, follow the plan provided by the system. If the protocol is not consistent with what the doctor thinks, the doctor will revise the protocol.

Locations

Country	Name	City	State
China	Chinese PLA General Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Chinese PLA General Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	MRI within 3 days after ablation	Postoperative MRI is used to determine whether the ablation zone completely covers the tumor and whether the size is appropriate	MRI within 3 days after ablation
Primary	local tumor progression	Follow up to observe whether local tumor progression occurs within 6 months after ablation	6 months